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Abstract
Today’s large, public databases of protein–small molecule interaction data are creating
important new opportunities for data mining and integration. At the same time, new
graphical user interface-based workflow tools offer facile alternatives to custom scripting
for informatics and data analysis. Here, we illustrate how the large protein-ligand data-
base BindingDB may be incorporated into KNIME workflows as a step toward the inte-
gration of pharmacological data with broader biomolecular analyses. Thus, we describe
a collection of KNIME workflows that access BindingDB data via RESTful webservices
and, for more intensive queries, via a local distillation of the full BindingDB dataset. We
focus in particular on the KNIME implementation of knowledge-based tools to generate
informed hypotheses regarding protein targets of bioactive compounds, based on no-
tions of chemical similarity. A number of variants of this basic approach are tested for
seven existing drugs with relatively ill-defined therapeutic targets, leading to replication
of some previously confirmed results and discovery of new, high-quality hits.
Implications for future development are discussed.
Database URL: www.bindingdb.org
Introduction
The last decade has seen a revolutionary rise in the open-
source availability of experimental data connecting proteins,
from humans and other organisms, with the drug-like small
molecules that bind them (1). For example, BindingDB, the
first public molecular recognition database (1–4) currently
serves users with over a million quantitative protein-ligand
interaction data, involving about 7000 proteins and 450 000
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small molecules. This dataset represents a unified collection
of quantitative binding data, which was assembled through
curation of scientific journals and US patents by BindingDB,
combined with ingestion of selected data from other import-
ant databases, notably ChEMBL (5), PubChem (6) and PDSP
Ki (7). BindingDB and other publicly accessible medicinal
chemistry resources now enable gene- and protein-oriented
bioinformatics information to be systematically linked with
drug discovery data, and are thus driving progress in interdis-
ciplinary fields like systems pharmacology (8, 9).
BindingDB provides a range of useful browsing and
search capabilities. As summarized in Table 1, these include
the ability to select an article by journal name, volume and
page number, and then retrieve its compounds and data in
machine-readable format; or to quickly access binding data
for a protein target of interest, based on its name, amino
acid sequence, UniProt (10) ID, or PDB (11) ID. A number
of BindingDB’s search capabilities are also accessible via
URL search templates, which generate human-readable
web-pages, and by RESTful webservices, which provide
data in simple XML formats. The latter offer a straightfor-
ward API by which software running remotely can inter-
actively access data from BindingDB. Alternatively, users
can download parts of the BindingDB dataset, or its entir-
ety, in several different formats, in order to enable entirely
local execution of codes that use BindingDB data. However,
this still requires software development, often through the
use of scripting languages, to carry out flexible analyses of
binding data or integrate it with the vast arrays of informa-
tion contained in other public bioinformatics resources or in
the user’s own local data archives.
Such challenges are increasingly addressed with flexible
workflow environments for data analysis (12), such as
Pipeline Pilot (13), Taverna (14), Kepler (15), Galaxy
(16–18), Loni Pipeline (19) and KNIME (20). The latter is
of particular interest here, as the computational chemistry
community was an early adopter of the KNIME
framework, and the open-source KNIME software is
associated with a freely distributed desktop environment.
The KNIME environment helps non-experts quickly
develop and implement algorithms through the use of hun-
dreds of individual ‘nodes’, each developed to perform a
particular task, and allowing user configuration for custom
data input and output. Nodes are developed in house at
KNIME, as well as by developers in the open-source and
for-profit communities, and are then made available as
downloads. For example, there is a large selection of nodes
for manipulation and analysis of chemical structures, such
as calculation of molecular weight, Markush enumeration,
evaluation of chemical similarity and other cheminfor-
matics tasks [CDK (21), RDKit (22), Schro¨dinger (23, 24),
ChEMBL (5), Open PHACTS (25), BioSolveIT (26)].
Thus, KNIME facilitates leveraging prior work by allow-
ing users to flexibly combine nodes contributed by various
developers in order to create new workflows.
The present study explores the combined usage of
KNIME and the BindingDB dataset, through development
and illustrative applications of a set of workflows, which
make exclusive use of nodes that are freely available. We first
describe two workflows which use KNIME nodes to interact
with BindingDB’s RESTful web services. The first retrieves
compounds known to bind a specific protein of interest,
based on its UniProt ID; and the second retrieves proteins
known to bind a specific compound of interest. These two
workflows are envisioned as building blocks which can be
incorporated into larger workflows that integrate protein-
ligand binding data into broader bioinformatics analyses.
We also describe a set of more complex workflows,
which implement the concept that a large database of
binding data can provide hypotheses about the mechan-
isms of action of bioactive compounds and predict or
explain the side effects of drugs (4, 27). Such hypotheses
are based on the transitivity principle that a compound A
which is chemically similar (28) to another compound B
has increased likelihood of binding the same proteins as
compound B (4, 27, 29–38). Accordingly, if A is found to
have a biological activity, its mechanism might be due to
binding the same proteins as compound B. Similarly, if A is
a drug, it might generate side-effects by binding the same
proteins as compound B. BindingDB’s Find My
Compound’s Targets (FMCT) tool (Table 1) implements
this idea, allowing users to enter one or more compounds
and use BindingDB data to predict their protein targets.
The present KNIME implementations of FMCT avoid
network delays and possible confidentiality issues by doing
Table 1. Commonly used BindingDB pages and information
sources
Browse by journal article citation bindingdb.org/bind/
ByJournal.jsp
Browse by text name of protein
target
bindingdb.org/bind/
ByTargetNames.jsp
Search or browse by UniProt ID of
target
bindingdb.org/bind/
ByUniProtids.jsp
Search or browse by target
sequence
bindingdb.org/bind/
BySequence.jsp
Search or browse by PDB ID bindingdb.org/bind/
ByPDBids_100.jsp
Documentation of query template
URLs
bindingdb.org/bind/
SearchTemplates.jsp
Documentation of BindingDB
RESTful services
bindingdb.org/Pathways/
BindingDBRESTfulAPI.jsp
‘Find my compound’s target’ tool bindingdb.org/bind/chem-
search/marvin/FMCT.jsp
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the processing locally, using a downloaded representation
of the necessary data from BindingDB. In addition to
detailing the implementation of these workflows, we also
evaluate their predictive performance by applying them to
seven drugs recently identified as having unknown or
uncertain mechanisms of action (32), and comparing the
results to those from the Similarity Ensemble Approach
(SEA) (35), which offers the same general functionality,
but uses additional statistics in an effort to enhance the
accuracy of the inferred compound–protein interactions. In
addition to attempting to assign therapeutic targets to
these drugs, we also seek to flag additional pharmaco-
logical activities, as these may suggest side-effects or drug-
repurposing opportunities.
Materials and methods
This section details the implementation of a set of KNIME
workflows which process and use BindingDB data. The
first subsection concerns two workflows which support
common BindingDB database queries, and the second
concerns several versions of the FMCT tool described
above.
Mining BindingDB for compounds and their
protein targets
The first two workflows use BindingDB’s web-services.
The Target2Compound workflow (Figure 1, top) takes as
input the UniProt ID(s) of one or more proteins, and
returns compounds known to bind the corresponding
protein(s) with an affinity (in nanomolar) above a user-
specified threshold. The Compound2Target workflow
(Figure 1, bottom) takes as input a single SMILES repre-
sentation of a compound, or a drawing from an interactive
KNIME chemical drawing node, contributed by
ChemAxon, and returns all proteins for which an affinity
measurement exists in BindingDB, along with the associ-
ated affinity data. The default mode is to search for exact
compound matches, but one may also search by chemical
Figure 1. Two KNIME workflows to query the BindingDB server. Target2Compound (top) retrieves compounds from BindingDB that are known bind-
ers of a protein target of interest. Separate columns are created in the output for the compounds’ unique BindingDB monomerID, followed by its
SMILES string, affinity types and affinity values. The collected results are stored in a table and can be written out to local disk. In this particular ex-
ample, UNIPROT P21802 is entered into the dialog box, and various compounds are returned. The Compound2Target workflow (bottom) retrieves
protein targets from the BindingDB database that are known to bind a particular compound of interest. Separate columns are created in the output
for monomerID, Protein Target, affinity types (IC50 or KI) and affinity values (in nanomolar). The results are stored in a table which can be written out
to local disk. In the given example, a sigma receptor binder is drawn in the MarvinSketch node, and the resulting output shows the expected targets,
with their respective known affinities for the compounds hits.
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similarity, measured on a scale of 0 to 1, where 1 is essen-
tially an exact match.
The use of BindingDB web-services for these two work-
flows ensures that users receive up-to-date information from
BindingDB, and takes advantage of built-in BindingDB
query capabilities, notably chemical aware queries using the
ChemAxon (39) toolkit. Both workflows utilize several
KNIME nodes for handling URL based data. For example,
the XML Reader node can upload a URL string, such as
http://bindingdb.org/axis2/services/BDBService/getLigands
ByUniprot?uniprot¼ in the case of Target2Compound,
and then retrieve the resulting XML document. This docu-
ment is then passed to a series of XPath nodes, which ex-
tract the appropriate data from the XML document.
Predicting the protein targets of a compound
We implemented multiple versions of FMCT (see
Introduction) as KNIME workflows. Each uses a different
chemical similarity metric, but the overall procedures are
essentially the same. In brief, the similarity of the query
compound(s) is computed against every other compound
in a reference database derived from BindingDB (see
below). The compounds in the reference database whose
similarity to the query compound is greater than a user-
specified threshold then are ranked according to their simi-
larity to the query compound, and the proteins known to
be bound by these top-ranked reference compounds are
identified. The initial list of top-scoring proteins identified
in this way normally includes repeats, because several
high-ranking compounds may bind one protein; such
repeats are eliminated by merging protein hits with identi-
cal UniProt IDs. The results are then formatted into a
report and presented to the user. Two sets of FMCT work-
flows were developed. One, designed for use with a single
query compound, provides a full listing of the potential
protein hits, with one protein per row. The second,
designed for use with multiple query compounds, provides
a reduced output table, in which each row lists one
compound and its top three protein hits. As this condensed
summary may not display some protein hits of interest, it is
worth noting that users can modify the workflow to
display more protein hits for each compound, or can make
more extensive changes to provide alternative reporting
formats.
These workflows do not use web-services, but instead
use a KNIME Table Reader node to load a local data
table of BindingDB data. The version of this table based
on BindingDB’s current dataset contains approximately
670 000 rows of BindingDB data, with one binding meas-
urement in each row, supplemented with multiple types
of pre-computed compound fingerprints and chemical
descriptors (see below). In effect, the data Table Reader
encapsulate much of BindingDB in a single KNIME node.
This approach maximizes performance and allows
users to work entirely on their local computer, instead
of having to upload possibly proprietary compounds
to the BindingDB server. In order to speed FMCT
calculations for use with large numbers of query com-
pounds, we also created a reduced version of the full
BindingDB table, which is filtered to include only a few
representative compounds for each protein, as detailed
below.
The FMCT method is based on the notion of chemical
similarity (40–45), and we tested several different similar-
ity metrics. Two of the metrics are based on chemical
fingerprints (46–48). One simply applies the Tanimoto
similarity (49) to the RDKit RDKit chemical fingerprint;
the choice of this particular fingerprint from RDKit’s
multiple options was made based on a suggestion from the
RDKit team (Greg Landrum, personal communication).
With a runtime of several minutes per query compound,
this is easily the fastest FMCT workflow we built. The
second fingerprint-based similarity metric was constructed
from multiple fingerprint-based metrics, as follows. The
current RDKit (22) and CDK (21) KNIME nodes
support a total of 14 different binary compound finger-
prints (Table 2). These can be compared with each other
using three different formulas, Tanimoto, Cosine BitVector
and Dice (28), for a total of 3 14¼ 42 available similarity
metrics. We applied all 42 methods to about 14 400
compound pairs drawn from known binders of the
dopamine receptor and the thrombin receptor, used
KNIME’s linear correlation node to generate a correlation
Table 2. Chemical fingerprint types available in the CDK and
RDKit packages in KNIME
CDK Standard
CDK Extended
CDK Estate
CDK PubChem
CDK MACCS
RDKit Morgan
RDKit FeatMorgan
RDKit AtomPair
RDKit Torsion
RDKit RDKit
RDKit Avalon
RDKit Layered
RDKit Pattern
RDKit MACCS
An enumeration of these types with each of the three similarity metrics
available (Tanimoto, Cosine BitVector and DICE) results in 42 separate scor-
ing methods.
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table connecting each similarity scoring method, and then
used KNIME’s correlation filter node to extract the 5 of 42
metrics that correlate least with each other (Table 3, and
Supplementary Figure S5), as detailed in Results. We then
implemented a version of FMCT in which the five similar-
ity scores for a given pair of compounds are simply
averaged with each other to yield an overall similarity
metric.
We also implemented versions of FMCT using a
maximum common substructure (MCS) similarity metric
(50–52) available in the KNIME MoSS MCSS Molecular
Similarity node. This node required special treatment,
however, as it produces an all-by-all comparison matrix
within a set of compounds, rather than comparing two
different sets of molecules. We addressed this by construct-
ing a (parallel) chunking loop which iterates through pairs
of molecules in two different columns by extracting each
molecular pair as a row, transposing the columns, and
computing the MCSS similarity of the pair. We then
adjusted the output to provide similarity on a scale of 0–1,
and used this in a separate FMCT workflow, which, again
assigns similarity hits and candidate targets based on a
user-specified similarity threshold.
Finally, even on a fast workstation, the MoSS MCSS
Molecular Similarity node requires about an hour to scan
one query compound across all 670 000 database entries
(see below), so this approach becomes unwieldy if one
wishes to run a large number of queries. The expectation
that two compounds with a high MCS similarity should
tend to also have a reasonably high fingerprint similarity
led to implementation a fourth FMCT approach, which
first runs the fast RDKit FP method, above, with some
default or user-selected similarity threshold; and then
re-ranks the resulting hits according to their MoSS MCSS
similarity scores.
Building the BindingDB tables for the FMCT workflows
The BindingDB tables used by the FMCT implementations
described above were constructed using KNIME, as
follows. A KNIME workflow, termed BDBBuilder
(Figure 2), begins by reading in the standard, tab-
separated-value file of all BindingDB data (http://tinyurl.
com/o7ppdj9), which has one compound-target measure-
ment per row; the version of this file used here has
1 043 465 rows. The workflow first filters out rows lacking
IC50 or KI measurements, or having affinity ranges,
Table 3. Similarity metrics and fingerprint types selected
from the linear correlation filter (see text)
Similarity metric Fingerprint type
KNIME Tanimoto RDKit MACCS
KNIME Tanimoto RDKit FeatMorgan
KNIME Tanimoto RDKit Torsion
KNIME Cosine Bitvector RDKit Morgan
KNIME Tanimoto CDK PubChem
Figure 2. BDBBuilder workflows. These read in BindingDB data, filter for appropriate IC50 and KI data, and convert SMILES strings to suitable molecu-
lar formats. The top workflow (BDBBuilder) generates RDKit and CDK molecules, multiple fingerprint types, and molecular descriptors. The bottom
workflow (BDBBuilderFast) is a simplified version that only generates RDKit RDKit molecules/fingerprints. In both versions, the final node of the work-
flow writes the resulting table to disk.
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indicated by the use of ‘<’ or ‘>’ symbols in the input file.
These filters reduce the number of rows to 677 825.
Additional rows were removed if their compounds failed in
the ‘RDKit From Molecule’ node’s MolSanitize function,
or did not create a ‘CDK Fingerprint’ node’s Fingerprint
string. This additional filter reduced the row count to
approximately 670 000. Each data row was then
supplemented with additional columns containing 2D
chemical fingerprints and descriptors for the compound in
the row. The fingerprints were generated using the
following cheminformatics packages available as KNIME
Community Contributions: CDK, Erlwood, Indigo and
RDKit, each of which has its own fingerprint generation
methods. In each case, the default settings of the nodes
were used in the configuration. Of the nearly 50 fingerprint
options provided, we selected a subset of 10 to retain,
based on correlation analysis of associated similarity scores
with the KNIME Correlation Filtering metanode. Thus,
the 10 fingerprints are those which gave the least corre-
lated similarity scores with each other, when used with a
specific similarity metric. The 38 descriptors available
from the RDKit package were similarly analyzed, and the
10 least correlated descriptors were added to the corres-
ponding data rows. The output file is saved as a KNIME
table, to be read in by a Table Reader node embedded in
the FMCT workflows. Running the entire BDBBuilder
workflow took about 3 h on an Intel Core i7 workstation.
As only fingerprints, not descriptors, are used in the final
workflows, we also developed a simpler version of this
workflow, called BDBBuilderFast (Figure 2), which
generates only RDKit RDKit molecules and fingerprints,
and takes roughly 30 min to run.
In applications where one wishes to predict protein tar-
gets for more than several hundred compounds, using the
full BindingDB tables (above) becomes time consuming.
We therefore used a KNIME workflow, termed
ClusteredData, to create a condensed version of the table,
which includes only representative binding compounds for
each protein target. We grouped compounds by their
protein targets, and then applied a Tanimoto similarity
method to their RDKit fingerprints, at a distance threshold
of 0.8, to define clusters of compounds within each pro-
tein-specific group. Several representative, high-affinity
compounds were then chosen as representatives from each
cluster, and inserted into a KNIME table with the same
structure as the full table described above. This procedure,
which required about 120 h of CPU time on a desktop Intel
Core i7 machine, resulted in a significant reduction of
number of compounds, from 670 000 to approximately
21 000, and thus greatly expedited the FMCT studies. The
consequences for the FMCT analysis are considered in
Results.
Results
This section presents the operation of the KNIME/
BindingDB workflows described in Materials and
Methods, and provides sample inputs and outputs.
Readers are encouraged to download (tinyurl.com/
jwqoulm and www.knime.org/example-workflows), test
them with their own queries, and use them as starting
points for their own applications. It is worth noting that
workflows which use BindingDB web-services may be
slowed unpredictably by network traffic, so extensive
usage may benefit from using the downloaded BindingDB
table (see Materials and Methods), as this enables queries
to be executed on the user’s computer, while also affording
maximum privacy. The setup instructions provided with
the downloadable package of workflows provides sugges-
tions for addressing issues that occasionally arise when
running KNIME, such as server timeout errors or memory
restrictions, through adjustments to the KNIME.INI con-
figuration file.
Finding compounds for targets and targets
for compounds, based on known binding
interactions
Operation of workflows
The Target2Compounds workflow (Figure 1, top) accepts
a protein target, specified with a UniProt accession
number, and returns compounds that this target binds with
an affinity better than a specified cutoff. The default cutoff
is 10mM (KI or IC50), but the user can optionally change
this by modifying the Affinity Cutoff node (Figure 1, top
left). Note that a UniProt accession number corresponds to
a single protein chain, and this search can yield compounds
binding multimeric proteins that contain one matching
chain and other non-matching chains. As shown in the
open dialog box (Figure 1, top left), the UniProt Primary
Accession Number should be entered into the UniProt
String Input node. The workflow is then executed by
right-clicking on the MarvinView node at the end of the
workflow. This triggers a query to BindingDB’s RESTful
API webservice, which returns query results in XML
format. Downstream nodes process the XML and parse it
for individual entries, generating a tabular output with one
row for each compound that binds the UniProt target. One
may then display the results by selecting the MarvinView
node’s Execute and Open Views option. Each row of the
resulting table (Figure 1, top right) contains a SMILES
string (transformed to a 2D structure in the MarvinView
Node display) for the respective compound, the primary
UniProt accession number of the desired target (along with
possible obsolete UniProt accession numbers for the same
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chain), the compound’s BindingDB Monomer ID, a
statement of the affinity type (KI or IC50) and then the
measured affinity (nM). Such tables can optionally be fed
into subsequent chemical informatics nodes to look for
common scaffolds or other patterns, combined with
Target2Compounds outputs for other targets to look
for overlaps or specificity patterns, or used as seeds for
chemical database searches. The table of compounds
can also be saved to disk in standard file formats, such as
SDF (53) or comma-separated value (CSV), for subsequent
use.
The Compound2Targets workflow (Figure 1, bottom)
is the inverse of Targets2Compounds: it retrieves protein
targets that bind a particular compound of interest. The
default mode is to accept a compound via a MarvinSketch
node (Figure 1, bottom left), which can be loaded with a
SMILES string or by manual drawing, and to retrieve
binding data for this exact compound, if it is found in
BindingDB. The user may, optionally, replace the default
exact-match search with a similarity search, by changing
parameters in the node labeled Similarity Threshold
(Figure 1, bottom left). Right-click and selecting Execute
and Open Views on the Interactive Table node (Figure 1,
bottom right) run the workflow and show the results. This
workflow converts the query compound to a SMILES
string and queries the BindingDB RESTful API webservice.
The resulting hits in XML format are read, processed and
parsed for individual entries. The output table provides a
list of the compound hits, identified and sorted by their
BindingDB Monomer IDs, along with all of BindingDB’s
available data on the affinities of these compounds for
their targets. As above, this table can be saved to disk in a
number of standard formats, or can be piped into
additional nodes added by the user for further data integra-
tion and processing.
Sample workflow usage and results
Mutations in the protein Fibroblast Growth Factor
Receptor 2 are associated with breast cancer (54), so it is
of interest to identify compounds which bind it. Using its
UniProt ID, P21802, to initiate a query with the
Target2Compounds workflow yields a substantial collec-
tion of binders (Figure 1, top). This workflow could
be embedded within a larger KNIME workflow which
would identify entire pathways of interest and use
Target2Compounds to annotate them with information
about known binders. Further, a user could browse for a
particular pathway of interest on this page: http://bind
ingdb.org/Pathways/pathways.jsp, click the BindingDB
link that lists all the known proteins and associated
UNIPROT IDs for that pathway, and then query each of
these in the Target2Compound workflow. Although not
currently set up to run a batch of targets, a simple KNIME
Loop construct would speed this process.
Alternatively, given a compound active against a target
of interest, one may wish to identify other targets of the
same compound, in order to study specific, polypharma-
cology, or mechanisms of toxicity. For example, the
compound in Figure 3 may already be known to bind
P. falciparum enoyl-acyl-carrier protein reductase
with submicromolar IC50 (55), but a query with
Compound2Targets reveals submicromolar potency
against other, varied targets, including a human immuno-
deficiency virus integrase and protein kinase PIM1. Such
information may be useful in selecting a compound as a re-
search probe or as a starting point for medicinal chemistry
Figure 3. Sample query and results of Compound2Target workflow. Left: Query compound (IUPAC, 3,5,7-trihydroxy-2-(3,4,5-trihydroxyphenyl)-4H-
chromen-4-one; SMILES, Oc1cc(O)c2c(c1)oc(-c1cc(O)c(O)c(O)c1)c(O)c2¼O; InChI, 1S/C15H10O8/c16-6-3-7(17)11-10(4-6)23-15(14(22)13(11)21)5-1-
8(18)12(20)9(19)2-5/h1-4,16-20,22H), which binds enoyl-acyl-carrier protein reductase with an IC50 of 400 nM. Right: Tabular output of
Compound2Target workflow, showing significant potency (nM) of the same compound (similarity¼ 1) against multiple targets.
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optimization; or it may be taken as a caution regarding
possible off-target effects of compounds in a specific struc-
tural class. Such applications are further developed in the
following subsection describing the FMCT method.
Using FMCT workflows to hypothesize new
targets for compounds
Operation of target-finding workflows
These workflows predict possible new protein targets for
compounds of interest. Straightforward applications of the
concept of chemical similarity (28), they search the
BindingDB dataset for compounds similar to a query
compound, and suggest the targets of these compounds as
potential targets of the query compound. In this way, the
FMCT functionality, which was already available on
the BindingDB web-site (bindingdb.org/bind/chemsearch/
marvin/FMCT.jsp), can be run locally in KNIME and,
optionally, incorporated into a user’s larger analytic
workflows.
We implemented and tested four FMCT variants, which
differ only in the similarity metrics they use. As detailed in
Materials and Methods, one uses Tanimoto similarity with
the RDKit RDKit chemical fingerprint; the second uses the
average of five different fingerprint-based similarity
metrics; the third uses a similarity metric based on the
maximal common substructure (MCS); and the fourth is
merely a re-ranking of the hits from the first metric based
on MCS similarity. This takes advantage of the speed of
the fingerprint method to identify similar compounds,
while using the slower MCS similarity metric to highlight
those similarities which also have the strongest substruc-
ture matches. It thus represents an attempt to obtain results
similar to those from the pure MCS method, but at lower
computational cost.
One set of FMCT workflows provides detailed results
for a single query compound. For these, the generalized
workflow for all four similarity metrics is shown in
Figure 4; the differences among the four similarity metrics
lie beneath this view, in the comparisons meta-node, which
performs the similarity calculations. To run any of these
workflows, the user double-clicks on the MarvinSketch
Input Compound node and uses the resulting window to
draw, paste or open a file with a small molecule compound
of interest. Next, one can optionally modify the green
Similarity Threshold and Affinity Cutoff nodes with
desired values. Finally, one right clicks the MarvinView
Predict Targets of My Compound node and selects Execute
and Open Views; when the run is complete, the green light
will turn on below this node. Right-clicking on it and
choosing View: MarvinView shows the output table of
similar compounds, their similarities to the input com-
pound and their associated targets. If too many results are
found, one may rerun the analysis with a higher (more
Figure 4. Workflow for FMCT methods designed for single query compounds. These workflows suggest what protein target(s) a compound of interest
is likely to bind, based on the targets known to bind similar compounds. The MarvinSketch mode allows entry of the query compound. The Affinity
Cutoff and Similarity Threshold nodes allow the user to set the stringency of these search parameters; affinity is specified in nM, and similarity on the
usual 0–1 scale. When the run is complete, the green light will turn on below the MarvinView node, and one can right-click on it and choose ‘View:
MarvinView’ to see the table of similar compounds, their similarities to the input compound and their associated targets. This figure depicts the
workflow for FMCT performed by single RDKit fingerprint similarity. Workflows which also use the average of five different fingerprint similarity
metrics, the RDKit RDKit results, sorted by MCS similarity, and a pure MCS similarity metric averaged, and single plus MCS resort (see main text)
have very similar top-level views. The differences lie in the ‘Comparisons’ meta-node, which performs the calculations.
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stringent) compound similarity threshold, and/or a lower
(more stringent) affinity cutoff (input as nanomolar).
A second set of these workflows provides less detailed
target predictions for batches of query compounds, which
are uploaded into an SDF Reader node. For the sake of a
compact output, these workflows generate a table of results
which does not show one suggested target per row, but in-
stead lists one compound per row, with only the top three
candidate targets in the associated columns. This allows for
quick viewing of results for a large set of query compounds,
but the incomplete target report can lead to missing an inter-
esting target which does not make the top three. Users may
therefore wish to adjust the output criteria to provide a
more complete report. It should also be noted that process-
ing a large batch of query compounds can become quite
time-consuming, particularly for the relatively slow calcula-
tion using the MCS metric. As detailed in Materials and
Methods, we sought to address this problem by using clus-
tering to generate a smaller reference set with representative
compounds; the results are summarized in the section
‘Accelerated target-finding with a reduced reference set’.
Application examples: hypothesizing new targets of
bioactive compounds
We applied the single-compound FMCT workflows, with
the four similarity metrics described above, to seven
compounds previously identified (32) as drugs with
unknown mechanisms of action. Previously, the SEA
method was used to suggest one or more therapeutic tar-
gets for each of these compounds, and new experiments
were done to determine whether they in fact bound the
suggested targets. Here, we compare the top target hits
from the present FMCT implementations (Table 4, col-
umns 1–4) with the published SEA hits (Table 4, first SEA
column). In addition, because the published SEA hits are
only a subset of those suggested by the SEA algorithm, and
because there may have been updates in the underlying
databases since that research was done, we also looked
more broadly at the SEA output for these seven drugs
(Table 4, second SEA column) by running them again on
the SEA website (http://sea.bkslab.org/search/). The prior
SEA analysis of these compounds focused on discovering
protein targets that might explain their therapeutic
Table 4a. Target hypotheses for cloperastine, a CNS-active cough suppressant, according to the present FMCT workflows
(columns 1–4), a prior SEA paper (32) (column 4) and the SEA website http://sea.bkslab.org/search/ (column 5)
RDKit similarity Five averaged similarities RDKit similarity Pure MCS SEA 2012
paper
SEA web
MCS re-sort
0.77–0.71 0.71–0.68 0.64–0.63 0.92–0.85 810128–1015
*Sodium-dependent
dopamine transporter
*Sodium-dependent
serotonin transporter
Sigma non-opioid
intracellular receptor 1
Histamine H1 receptor
Muscarinic acetylcholine
receptor M5
*Muscarinic acetylcholine
receptor M1
Muscarinic acetylcholine
receptor M2
Muscarinic acetylcholine
receptor M3
Muscarinic acetylcholine
receptor M4
Potassium voltage-gated
channel subfamily H
member 2
*Sodium-dependent
dopamine transporter
*Sodium-dependent
serotonin transporter
*Norepinephrine
transporter
Sigma non-opioid
intracellular receptor 1
*Sodium-dependent
noradrenaline
transporter
5-hydroxytryptamine
receptor 2
D(2) dopamine receptor
Alpha-1A adrenergic
receptor
Histamine H1 receptor
D(3) dopamine receptor
Sigma non-opioid intra-
cellular receptor 1
Histamine H1 receptor
Muscarinic acetylcholine
receptor M5
*Muscarinic acetylcholine
receptor M1
Muscarinic acetylcholine
receptor M2
Muscarinic acetylcholine
receptor M3
Muscarinic acetylcholine
receptor M4
Potassium voltage-gated
channel subfamily H
member 2
Solute carrier family 22
member 1
Solute carrier family 22
member 2
Acetylcholine-binding
protein
CHRNA7-FAM7A fu-
sion protein
Dopamine D3 receptor
*Dopamine D4
receptor
Dopamine Receptor D2
*Leukotriene A4
hydrolase
Dopamine D1 receptor;
DA D1 receptor
Dopamine receptor D5
Neuronal acetylcholine
receptor subunit
beta-2
Sodium- and chloride-
dependent GABA
transporter 1
r receptor
Histamine
H1 receptor
Histamine
H3 receptor
*Dopamine
transporter
*Serotonin
transporter
*Leukotriene A4
hydrolase
*Sigma opioid
receptor
Histamine H3
receptor
*Norepinephrine
transporter
Dopamine D4
receptor
*Transporter
Serotonin 4
(5-HT4)
receptor
*Muscarinic
acetylcholine
receptor M1
The SEA web-search used the ChEMBL v. 16 database, a binding affinity cutoff of 10 mM, and Scitegic ECFP4 fingerprints. In each case, outputs were grouped
by unique Targets, and the top 10 hits are shown, with the best hits at the top, except for the SEA 2012 paper data, which are not ranked. FMCT Target names
are drawn from UniProt (10). SEA web-site Target names are taken as reported. Bold indicates a match between FMCT and the published SEA results, and aster-
isks indicate matches between FMCT and SEA results from the SEA web-site. The range of similarity values for the listed target predictions are given under each
column heading, where available, as generated by the corresponding methods.
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mechanisms. Here, we consider whether new target predic-
tions made by FMCT could account not only for thera-
peutic mechanism but also for other known
pharmacological activities, such as side-effects. We now
consider each of the drugs in detail.
Cloperastine
Cloperastine (Figure 5, top left) is a cough-suppressant
which acts to suppress the CNS cough center (56).
Discovered in studies of derivatives of the first-generation
antihistamine diphenhydramine (Figure 5, top right) (57),
it also possesses antihistaminic activity. The SEA study
suggested and experimentally confirmed binding of
cloperastine to the sigma receptor, and noted that this
could explain its antitussive activity, based on the known
relationship of activity at the sigma receptor type 1 to
cough (58). (It is perhaps worth noting, however, that not
only binding but also activation of the receptor would
presumably be required to further verify this proposal.)
Unsurprisingly, given the origin of cloperastine, it was also
predicted and found to bind two subtypes of the histamine
receptor. The SEA web-site similarly suggests sigma opioid
receptor and one of the histamine receptor types as a top
hits, but also assigns high scores (low E-values) to
transporters of serotonin, dopamine and norepinephrine,
as well as two neurotransmitter receptors, and, perhaps
surprisingly, the enzyme leukotriene A4 hydrolase.
The FMCT results overlap strongly with those from
SEA (Table 4a). Thus, all three of the fingerprint-based
FMCT methods include the sigma receptor type 1 and
histamine receptor type 1 among the top 10 hits (bold
font). The latter was determined to be a hit for cloperastine
based on this compound’s RDKit fingerprint similarity of
0.71 to diphenhydramine. Almost all of the additional hits
from the SEA web-site also are hits for the fingerprint-
based FMCT methods (Table 4a, asterisks). In addition,
the unexpected enzyme hit, leukotriene A4 hydrolase,
appears in only one of our methods, the pure MCS
approach; the compound that led to this hit (Figure 5,
bottom) has a very high MCS similarity score of 0.92 with
cloperastine. An RDKit fingerprint similarity of these two
compounds is only 0.41, which explains why it was not
identified in any of our other methods. The higher
similarity determined by MCS may be due to the likeness
of individual substituents; one may imagine breaking
cloperastine at the ether group and moving this, along with
the connected piperidine ring, to the methylene joining the
two phenyl groups. Whether the activities of these two
compounds are similar will depend in large part on the 3D
configuration and importance of these individual substitu-
ents in binding interactions with the protein target; readers
are encouraged to decide for themselves whether the two
compounds are indeed structurally similar.
More interestingly, one of the new FMCT hits gains
substantial plausibility from external data. Thus, two
FMCT methods suggest an interaction with the D(2)
dopamine receptor, and a search of PubChem reveals a
screening hit for cloperastine itself with the D(2) dopamine
receptor (59). (Note that this datum is not in BindingDB,
because BindingDB imports only confirmatory PubChem
BioAssay data, and this is only a primary screening result.)
Intriguingly, there are clinical case reports of dystonic
reactions to cloperastine (60, 61), and dystonia is
associated with agents that block the D(2) dopamine
receptor. The SEA web-site similarly suggests the D4
dopamine receptor, though not D2, as a potential target of
Cl
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Figure 5. Cloperastine (top left), diphenhydramine (top right) and a known 1.8-mM inhibitor of leukotriene A4 hydrolase (bottom).
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cloperastine. In summary, the straightforward chemical
similarity methods implemented in FMCT yield a new
target prediction which is encouragingly consistent with
both in vitro and clinical data.
Nepinalone
Nepinalone (Figure 6), another cough suppressant, is
documented by a remarkably scant literature. The SEA
method again identified the sigma receptor as a target of
this drug, and confirmed binding in vitro, thus offering a
potential therapeutic mechanism. All four FMCT methods
similarly identified sigma receptor 1 as a top hit; and four
other hits from the SEA web-site also appear in the FMCT
results (Table 4b). For example, a steroid isomerase en-
zyme is highly ranked by SEA and two fingerprint methods
in FMCT. It is thus encouraging that the sigma receptor
and the isomerase have similar protein sequences, and that
inhibitors of the isomerase bind the sigma receptor (62).
The isomerase link might point to a novel side-effect
mechanism for nepinalone, but this possibility is difficult
to assess, due to the paucity of information on this drug.
More generally, the top 10 targets suggested by the
FMCT methods are more varied than those suggested for
cloperastine, as they include additional enzymes and
receptors. This variety may trace in part to the lower range
of chemical similarities here than for cloperastine: the
number of other compounds and hence candidate targets
expands rapidly as one lowers the chemical similarity
threshold. Although it is not clear that any particular
similarity cutoff should be applied when one assesses the
results of this type of analysis, it is clear that less
confidence should be placed in target predictions based on
lower similarity scores.
Clemastine
Clemastine (Figure 7) is yet a third antitussive, which also
has clinical antihistaminic and anticholinergic effects. The
SEA study predicted and experimentally confirmed the
sigma 1 receptor as a protein target of this compound.
Perhaps surprisingly, then, the sigma 1 receptor does not
Table 4b. Target hypotheses for nepinalone
RDKit similarity Five averaged
similarities
RDKit similarity Pure MCS SEA 2012
paper
SEA web
MCS re-sort
0.95-0.64 0.68–0.54 0.63–0.58 0.74–0.70 31022 – 46
*Sigma non-opioid
intracellular receptor 1
D(2) dopamine receptor
*3-beta-hydroxysteroid-
Delta(8),Delta(7)-
isomerase
C-8 sterol isomerase
D(3) dopamine receptor
Vesicular acetylcholine
transporter
Aminopeptidase M
5-hydroxytryptamine re-
ceptor 2A
*Nociceptin receptor
Corticosteroid 11-beta-
dehydrogenase isozyme
1
*Sigma non-opioid
intracellular receptor 1
*3-beta-hydroxysteroid-
Delta(8),Delta(7)-
isomerase
C-8 sterol isomerase
D(2) dopamine receptor
Vesicular acetylcholine
transporter
Sigma opioid receptor
Nociceptin receptor
*Histamine H3 receptor
Muscarinic acetylcholine
receptor M2
5-hydroxytryptamine
receptor 2A
Vesicular acetylcholine
transporter
*Nociceptin/Orphanin
FQ, NOP receptor
Alpha-2A adrenergic
receptor
Alpha-2C adrenergic
receptor
Adrenergic Alpha2
Adrenergic Alpha2D
Alpha-2B adrenergic
receptor
*Sigma non-opioid
intracellular receptor 1
Glutamate-NMDA-
MK801
5-hydroxytryptamine
receptor 3A
Dopamine D3 receptor
Dopamine Receptor D2
Glutamate receptor ion-
otropic, NMDA 2B
Serotonin Receptor 1A
*Sigma opioid receptor
Vesicular acetylcholine
transporter
Sodium-dependent
dopamine transporter
Sodium-dependent nor-
adrenaline transporter
Sodium-dependent sero-
tonin transporter
Histamine H1 receptor
r receptor *Sigma opioid
receptor
*3-beta-
hydroxysteroid-
Delta(8),Delta(7)-
isomerase
Histamine
N-methyltransferase
*Histamine H3
receptor
*Nociceptin receptor
*Sigma-1 receptor
Sodium channel
protein type II alpha
subunit
Serotonin 2c (5-HT2c)
receptor
Histamine H1
receptor
Muscarinic acetylcho-
line receptor M5
See Table 4a for details.
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Figure 6. Nepinalone.
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appear among the top-ranked SEA web-site hits (Table 4c).
Correspondingly, none of the FMCT methods identifies
this target (Table 4c) either. There is significant overlap
among the FMCT and SEA web-site predictions,
particularly if one combines the subtypes of the muscarinic
acetylcholine receptor (Table 4c); and the prediction of
muscarinic activity is consistent with experimental
evidence that clemastine promotes neuronal remyelination
through activity at muscarinic receptors in oligodendro-
cytes (63).
The present FMCT results also go beyond the results dis-
played by SEA, as FMCT reveals that clemastine itself has
been shown to bind the lipid storage regulatory proteins
perilipin 1 and 5 with 11 and 15 mM potencies, respectively
(64). Although a literature search did not uncover any evi-
dence that clemastine’s binding of the perilipins is clinically
relevant, this activity could ultimately prove significant. The
fact that these exact matches were not identified by web-
based SEA tool may be attributed to its use of a 10-mM af-
finity threshold, which is not met by the 11 and 15mM
affinities of clemastine for the perilipins.
Benzquinamide
Benzquinamide (Figure 8, left) is an obsolete antiemetic
and anxiolytic drug (65). Although it is typically described
as having antihistaminic and antimuscarinic activity
(http://www.drugbank.ca/drugs/DB00767), the SEA ana-
lysis did not identify the histamine or muscarinic acetyl-
choline receptors as likely targets, and in fact went on to
exclude these experimentally as high-affinity targets (32).
Instead, the SEA analysis suggested the alpha-2 adrenergic
receptor as a protein target, and this binding was con-
firmed experimentally. The similarity of known binders of
the alpha-2 adrenergic receptors and binders of dopamin-
ergic receptors then led to prediction and experimental
confirmation that benzquinamide also binds to the dopa-
mine (D2) receptor. Curiously, none of the FMCT methods
suggests adrenergic receptors as targets, and these are also
absent from the SEA web-site predictions. On the
other hand, two of the fingerprint-based FMCT methods
immediately yield the D(2) dopamine receptor as top hits
Table 4c. Target hypotheses for clemastine
RDKit similarity Five averaged
similarities
RDKit similarity Pure MCS SEA 2012 paper SEA web
MCS re-sort
1.00–0.70 0.92–0.58 0.92–0.64 1.00–0.79 101029– 427
Perilipin-1
Perilipin-5
*Solute carrier family 22
member 1
Muscarinic acetylcholine
receptor M1
Sodium-dependent
dopamine transporter
Sodium-dependent
serotonin transporter
Norepinephrine
transporter
Muscarinic acetylcholine
receptor M2
D(2) dopamine receptor
D(3) dopamine receptor
Perilipin-1
Perilipin-5
*Solute carrier family
22 member 1
Neuronal acetylcholine
receptor subunit
alpha-7
Neuronal acetylcholine
receptor; alpha4/beta2
Nicotinic acetylcholine
receptor alpha4/beta2/
alpha5
*Neuronal acetylcholine
receptor subunit
alpha-10
Sodium-dependent
dopamine transporter
Sodium-dependent
serotonin transporter
Norepinephrine
transporter
Perilipin-1
Perilipin-5
*Solute carrier family 22
member 1
Norepinephrine
transporter
Sodium-dependent
serotonin transporter
Sodium-dependent dopa-
mine transporter
Muscarinic acetylcholine
receptor M1
Muscarinic acetylcholine
receptor M2
Sodium-dependent dopa-
mine transporter
D(3) dopamine receptor
*Solute carrier
family 22
member 1
Perilipin-1
Perilipin-5
Sodium channel
protein type 2
subunit alpha
D(3) dopamine
receptor
D(4) dopamine
receptor
D(2) dopamine
receptor
Sodium-dependent
dopamine
transporter
Muscarinic
acetylcholine
receptor M2
*Histamine H1
receptor
r receptor *Solute carrier family
22 member 1
Muscarinic acetylcho-
line receptor M5
Muscarinic acetylcho-
line receptor M4
Serotonin 6 (5-HT6)
receptor
Cytochrome P450
2C19
Histamine H2
receptor
*Histamine H1
receptor
*Neuronal acetylcho-
line receptor protein
alpha-10 subunit
Synaptic vesicular
amine transporter
C-X-C chemokine re-
ceptor type 7
See Table 4a for details.
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Figure 7. Clemastine.
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(Table 4d), whereas the SEA web-site provides the similar
D(1) dopamine receptor. A number of other top hits also
are common between the SEA web-site and the FMCT re-
sults, but we were not able to uncover external confirm-
ation or clinical correlates for these.
All three fingerprint-based FMCT analyses furthermore
predict that benzquinamide may bind multidrug resistance
protein 1, also known as P-glycoprotein. Emetine, the simi-
lar compound in BindingDB which led to this prediction is
shown in Figure 8 (right). Given this prediction, we did a
literature search, which yielded apparent confirmation in a
paper (66) stating that ‘Benzquinamide inhibits P-
glycoprotein-mediated drug efflux and potentiates anti-
cancer agent cytotoxicity in multidrug resistant cells’. It is
not immediately clear why the SEA method did not make
this prediction, given the chemical similarity of benzquina-
mide to emetine, and the fact that emetine binds the multi-
drug resistance protein with an affinity better than 10mM.
Lobenzarit
The drug lobenzarit (Figure 9, left) is an immunomodula-
tor (67) which is used to treat rheumatoid arthritis. The
prior SEA analysis suggested and experimentally confirmed
inhibition of COX-2 by lobenzarit, leading to the
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Figure 8. Benzquinamide (left) and emetine (right), a chemically similar compound identified by FMCT that is known to bind multidrug resistance
protein 1.
Table 4d. Target hypotheses for benzquinamide
RDKit similarity Five averaged
similarities
RDKit similarity Pure MCS SEA 2012
paper
SEA web
MCS re-sort
0.86–0.80 0.64–0.58 0.84–0.77 0.64–0.52 101077–1002
*Synaptic vesicular
amine transporter
*Dipeptidyl peptidase 4
Peptidyl-prolyl cis–
trans isomerase
FKBP1A
Cytochrome P450 2D6
*D(1A) dopamine
receptor
D(2) dopamine
receptor
Multidrug resistance
protein 1
COUP transcription
factor 2
Nuclear receptor ROR-
alpha
*Putative hydrolase
RBBP9
Synaptic vesicular
amine transporter
*Dipeptidyl peptidase 4
*Orexin receptor type 1
*Orexin receptor type 2
Cytochrome P450 2C9
Cytochrome P450 2D6
COUP transcription
factor 2
Multidrug resistance
protein 1
Nuclear receptor
ROR-alpha
*Putative hydrolase
RBBP9
Synaptic vesicular
amine transporter
*Dipeptidyl peptidase 4
Multidrug resistance
protein 1
COUP transcription
factor 2
Nuclear receptor
ROR-alpha
*Putative hydrolase
RBBP9
Steroidogenic factor 1
D(2) dopamine
receptor
*D(1A) dopamine
receptor
Melatonin receptor
type 1B
Synaptic vesicular
amine transporter
*Dipeptidyl
Peptidase IV
(DPP-IV)
Sodium-dependent
dopamine
transporter
Norepinephrine
transporter
Integrin beta-3
Acetylcholinesterase
Interstitial
collagenase
Collagenase 3
5-hydroxytrypt-
amine receptor 4
Kallikrein-related
peptidase 5
preproprotein
Dopamine
receptor (D2,
D3, D4)
Adrenoceptor
a2 receptor
*Synaptic vesicular
amine transporter
*Orexin receptor 1
*Orexin receptor 2
Melatonin receptor 1B
*Putative hydrolase
RBBP9
*Dipeptidyl peptidase IV
Small conductance cal-
cium-activated potas-
sium channel protein 1
Carbonic anhydrase XIV
*Dopamine D1 receptor
Carbonic anhydrase VII
See Table 4a for details.
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suggestion that COX-2 inhibition may be the therapeutic
mechanism of this drug. Somewhat surprisingly, COX-2
does not rise to the top 10 of the SEA web-site’s target
rankings. However, it does appear, listed as prostaglandin
G/H synthase 2, in two of the FMCT rankings, along with
the closely related enzyme prostaglandin G/H synthase 1
(Table 4e). Two hits from the SEA web-site list, both
alpha-keto reductases, do appear in all four of the FMCT
lists, but there is otherwise little concordance between the
two methods.
All four FMCT methods also predict binding of loben-
zarit to a phospholipase A2, a prediction not made by
SEA. The phospholipase inhibitor responsible for this pre-
diction, tolfenamic acid (Figure 9, top right), is clearly
HO O
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Figure 9. Lobenzarit (top left), tolfenamic acid (top right, a known inhibitor of phospholipase A2), diclofenac (bottom left) and niflumic acid (bottom
right).
Table 4e. Target hypotheses for lobenzarit
RDKit similarity Five averaged
similarities
RDKit similarity Pure MCS SEA 2012
paper
SEA web
MCS re-sort
0.91–0.77 0.76–0.68 0.82–0.70 0.85–0.80 1010156– 220
*Aldo-keto reductase family
1 member C3
*Aldo-keto reductase family
1 member C2
Hexokinase
Androgen receptor
Cysteine protease ATG4B
Phospholipase A2
Anthranilate
phosphoribosyltransferase
17-beta-Hydroxysteroid
Dehydrogenase 5 (17-
beta-HSD5, AKR1C3)
NAD-dependent protein
deacetylase sirtuin-1
Carbonic anhydrase 1
*Aldo-keto
reductase family 1
member C3
*Aldo-keto
reductase family 1
member C2
Hexokinase
Androgen Receptor
(AR)
Cysteine protease
ATG4B
Phospholipase A2
Androgen receptor
Aldo-keto reductase
family 1 member C1
Prostaglandin G/H
synthase 2
Prostaglandin G/H
synthase 1
*Aldo-keto reductase family
1 member C3
*Aldo-keto reductase family
1 member C2
Hexokinase
Androgen receptor
Cysteine protease ATG4B
Phospholipase A2
Anthranilate
phosphoribosyltransferase
17-beta-Hydroxysteroid
Dehydrogenase 5 (17-
beta-HSD5, AKR1C3)
NAD-dependent protein
deacetylase sirtuin-1
Carbonic Anhydrase IX
*Aldo-keto reductase
family 1 member C2
*Aldo-keto reductase
family 1 member C3
Aldo-keto reductase
family 1 member C1
Androgen Receptor
Prostaglandin G/H
synthase 1
Prostaglandin G/H
synthase 2
Cysteine protease
ATG4B
Phospholipase A2
17-beta-
Hydroxysteroid
Dehydrogenase 5
(17-beta-HSD5,
AKR1C3)
Carbonic Anhydrase IX
COX-2 *Aldo-keto reductase
family 1 member C2
*Aldo-keto-reductase
family 1 member C3
Beta-ketoacyl-ACP
synthase III
Glutamate receptor
ionotropic kainate 1
UDP-galactose
4-epimerase
Aldo-keto reductase
family 1 member C1
Interleukin-8
Hydroxycarboxylic
acid receptor 2
Calcium-activated
potassium channel
subunit alpha-1
Liver glycogen
phosphorylase
See Table 4a for details.
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similar to lobenzarit (Figure 9, top left). Tolfenamic acid is
actually an existing non-steroidal anti-inflammatory drug,
and hence a known COX (cyclooxygenase) inhibitor, in ac-
cord with the SEA and FMCT hits on this target.
BindingDB’s additional contribution is that tolfenamic
acid is a 7.7-mM inhibitor of phospholipase A2. This result
derives from a counterscreen (PubChem AID 588400), ra-
ther than a primary screen. Interestingly, phospholipases
A2 have been implicated in a variety of inflammatory and
autoimmune disorders, including rheumatoid arthritis, one
of lobenzarit’s indications. We therefore tested lobenzarit
in the same phospholipase inhibition assay that turned up
tolfenamic acid as an inhibitor, while also re-testing tolfe-
namic acid. Contrary to the prediction based on molecular
similarity, lobenzarit showed no significant inhibition at
concentrations up to 300 mM, whereas tolfenamic acid was
found to have an IC50 of 20mM, similar to the previously
reported value of 7mM; see Supplementary Figure S6. This
result clearly argues against the target hypothesis. On the
other hand, it seems equally clear that one would not want
to miss uncovering the chemical similarity of lobenzarit to
tolfenamic acid evident in Figure 9; and it is still of interest
to consider whether lobenzarit might inhibit another
phospholipase involved in inflammatory pathways. Some
further support for this concept is afforded by recent co-
crystal structures of the similar (Figure 9) anti-inflamma-
tory agents diclofenac [2b17 (68)] and niflumic acid [1td7
(69)] with a snake phospholipase A2 (UniProt
PA2A3_NAJSG) having 51% sequence identity with
human phospholipase A2 (UniProt PA21B_HUMAN).
Cyclobenzaprine
Cyclobenzaprine (Figure 10) is a centrally acting muscle re-
laxant. Its known activity at the 5-hydroxytryptamine
(serotonin) receptor 2A might explain its therapeutic activ-
ity (http://www.drugbank.ca/drugs/DB00924), and it may
also act at adrenergic receptors (70). The SEA analysis fur-
ther predicted and confirmed binding to the M1, M2 and
M3 muscarinic acetylcholine receptors, and suggested that
this hitherto unknown interaction could play an important
role in cyclobenzaprine’s therapeutic activity. (It is perhaps
worth mentioning that, although modulation of muscarinic
receptors might explain changes in smooth muscle tone, it
seems less clear that it could account for the relaxation of
skeletal muscle, for which cyclobenzaprine is used.) The
SEA analysis also suggested and confirmed binding at the
H1 histamine receptor. Both the present FMCT methods
(Table 4f) and the SEA web-server provide very similar tar-
get predictions, especially if one lumps together different
subtypes of each receptor. All of the FMCT prediction
methods also suggest several new targets, but we were un-
able to find confirmatory data in the literature; some of
these could be of interest to follow up experimentally.
Nefopam
Nefopam (Figure 11, left) is a centrally active analgesic, for
which the SEA publication suggested and confirmed binding
to serotonin receptors. Allowing less compelling E-values
furthermore turned up the dopamine transporter, which was
also confirmed as a hit, along with the serotonin and nor-
epinephrine transporters. The present FMCT methods
(Table 4g) predict primarily muscarinic receptor and hista-
mine receptor binding, in agreement with the SEA web-
server, but we were unable to find literature bearing on these
predictions. It might be of concern that the top 10 FMCT
hits did not include the serotonin and norepinephrine trans-
porters, but these do appear a little lower in the lists; e.g.
positions 20–22 for the single RDKit fingerprint method,
where they appear with chemical similarity scores of 0.61.
Comparison of fingerprint versus MCS similarity in FMCT
Inspection of Table 4 reveals that the fingerprint-based
FMCT methods tend to give similar target predictions,
whereas the pure MCS method often generates distinctive
results. It is instructive to examine the specific example of
cloperastine, for which pure MCS suggests leukotriene A4
hydrolase as a protein target, but the fingerprint methods
do not. The similar compound in BindingDB which gener-
ates this MCS similarity hit is shown in Figure 5 (bottom),
where it may be compared with cloperastine itself
(Figure 5, top left). Perhaps not surprisingly, the RDKit fin-
gerprint similarity between these two compounds is only
0.41. The pure MCS similarity metric also yields distinct
target suggestions for cyclobenzaprine (aldose reductase)
and nefopam (HIV-1 reverse transcriptase; see Figure 11,
right). The fingerprint approaches appear to correlate
somewhat more strongly with the web-based SEA results
than does the pure MCS approach, probably because the
similarity metric underlying SEA is a type of chemical fin-
gerprint, rather than one based on MCS. Overall, the pure
MCS approach provides distinctive target suggestions
that may merit attention. However, it is far more time-
consuming than the fingerprint methods, so we tested a
N
Figure 10. Cyclobenzaprine.
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hybrid approach in which MCS similarities were computed
for only the most similar fingerprint hits, and the finger-
print hits were re-ranked by MCS similarity. Although the
resulting method is faster, it does not succeed at highlight-
ing the interesting hits found by pure MCS, as evident by
inspection of Table 4.
Accelerated target-finding with a reduced reference set
The fingerprint-based FMCT methods require a few mi-
nutes on a single commodity computer to scan a query
compound against the full 670 K compound reference set,
whereas the MCS method requires over an hour. These cal-
culations thus can become time-consuming in applications
where one wishes to process multiple compounds, such as
a commercial compound catalog. One solution is to use
parallel processing to reduce the wall-clock time, but it is
also of interest to reduce the overall computational re-
quirements. We conjectured that similar results might be
returned if compounds were scanned not against the full
reference set, but instead against a reduced set generated
by clustering all compounds in the full set based on RDKit
fingerprint similarity, and keeping only one representative
compound from each cluster (see Materials and Methods).
The reduced reference set contained only 21K compounds,
a roughly 30-fold reduction, and the FMCT workflows
were accordingly accelerated; for example, the pure MCS
workflow requires only a few minutes per compound when
used with the reduced reference set. However, the
increased speed came at the cost of a significantly reduced
ability to recover important hits. For example, although
the full reference set allowed FMCT to rediscover 13 of the
20 confirmed target hits reported in the SEA paper for
the seven drugs (as well as several plausible new targets),
the present reduced reference set turned up only four. To il-
lustrate the performance of the clustering technique, and
perhaps an explanation for the lack of predictions with the
reduced set, we highlight two cluster sets from a single tar-
get, Dopamine D4 (Figure 12). As is apparent by looking
at these compound structures, the diversity within the
Table 4f. Target hypotheses for cyclobenzaprine
RDKit similarity Five averaged
similarities
RDKit similarity Pure MCS SEA 2012
paper
SEA web
MCS re-sort
0.85–0.85 0.77–0.77 0.79–0.79 0.91–0.68 101046 – 303
D(2) dopamine
receptor
*5-hydroxytryptamine
receptor 2A
Histamine H1 receptor
5-hydroxytryptamine
receptor 1A
*Muscarinic acetyl-
choline receptor M5
Muscarinic acetylcho-
line receptor M1
Muscarinic acetylcho-
line receptor M2
Muscarinic acetylcho-
line receptor M3
*Muscarinic acetyl-
choline receptor M4
Norepinephrine
transporter
*Muscarinic acetyl-
choline receptor M5
*5-hydroxytryptamine
receptor 2A
5-hydroxytryptamine
receptor 1A
Histamine H1 receptor
Muscarinic acetylcho-
line receptor M1
Muscarinic acetylcho-
line receptor M2
Muscarinic acetylcho-
line receptor M3
*Muscarinic acetyl-
choline receptor M4
Norepinephrine
transporter
Sodium-dependent
noradrenaline
transporter
D(2) dopamine
receptor
5-hydroxytryptamine
receptor 2A
*5-hydroxytryptamine
receptor 2C
5-hydroxytryptamine
receptor 6
*Muscarinic acetyl-
choline receptor M5
Norepinephrine
transporter
5-hydroxytryptamine
receptor 1A
Histamine H1 receptor
Muscarinic acetylcho-
line receptor M1
Muscarinic acetylcho-
line receptor M2
Adenosine A3
Receptor
Histamine H1
receptor
Sodium-dependent
noradrenaline
transporter
Sodium-dependent
dopamine
transporter
Aldose reductase
Protein skinhead-1
*Alpha-1A adrenergic
receptor
D(2) dopamine
receptor
Sigma non-opioid
intracellular
receptor 1
D(1A) dopamine
receptor
Muscarinic
M1 receptor
Muscarinic
M2 receptor
Muscarinic
M3 receptor
Histamine
H1 receptor
*Histamine H1
receptor
*Alpha-1a adrenergic
receptor
*Muscarinic acetylcho-
line receptor M4
Serotonin 2b (5-HT2b)
receptor
*Serotonin 2c (5-HT2c)
receptor
*Muscarinic acetylcho-
line receptor M5
Alpha-1b adrenergic
receptor
Alpha-2b adrenergic
receptor
Pleiotropic ABC efflux
transporter of mul-
tiple drugs
Histamine H2 receptor
See Table 4a for details.
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Figure 11. Nefopam (left) and a 40-mM inhibitor of HIV-1 reverse tran-
scriptase inhibitor (right) identified by the pure MCS metric as similar to
nefopam.
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cluster sets varies considerably, as does the value of select-
ing a representative member of each set at random.
Packaging and dissemination of workflows
and data tables
The main user workflows described above, and the data
tables they use, are available for download at the websites
for BindingDB (tinyurl.com/jwqoulm). They also can be
accessed through the KNIME desktop, via the KNIME
Explorer, under EXAMPLES, as described here: http://
www.knime.org/example-workflows, and filtering for
‘BindingDB’. In all cases, the left-most nodes displayed in
the workflow accept user input, and the right-most nodes
collect and display output. The output is displayed in a
KNIME table by default, but can be also saved in a variety
of formats (CSV, SDF, MOL, etc.) or channeled to other
workflows/nodes for follow-on analysis. The same reposi-
tories also provide a number of related utility workflows,
such as the BDBBuilder and ClusteredData workflows,
used to produce BDBBuilder Table and ClusteredData
Table, respectively. These may be used to update the data
tables used by the FMCT workflows as new BindingDB
data become available on the BindingDB Download page.
Discussion
Integration of BindingDB into KNIME workflows
The integration of BindingDB with KNIME workflows
sets the stage for incorporation of BindingDB data into
a wider range of applications, which can take advantage
of the growing ecosystem of KNIME nodes and
workflows supporting chemical informatics, bioinfor-
matics and data analytics (https://tech.knime.org/knime-
community) (71). Various use-cases may be envisioned,
for example:
• Target2Compounds may be used to annotate biomolecu-
lar signaling pathways with information about available
small molecule modulators, as a step to moving from sys-
tems biology to systems pharmacology.
• FMCT workflows can suggest mechanistic targets for
compounds discovered to be active in high-
throughput phenotypic assays, such as ones in which
cellular changes induced by millions of compounds are
detected by microscopy and categorized by automated
image analysis.
• The Compound2Targets and FMCT workflows may find
application screening commercial catalogs for known
and potential activities.
Table 4g. Target hypotheses for nefopam
RDKit similarity Five averaged similarities RDKit similarity Pure MCS SEA 2012
paper
SEA web
MCS re-sort
0.72–0.72 0.59–0.59 0.66–0.66 0.88–0.88 21019– 401
Potassium voltage-gated
channel subfamily H
member 2
*Muscarinic acetylcholine
receptor M5
*Histamine H1 receptor
Muscarinic acetylcholine
receptor M1
Muscarinic acetylcholine
receptor M2
Muscarinic acetylcholine
receptor M3
Muscarinic acetylcholine
receptor M4
Solute carrier family 22
member 1
Solute carrier family 22
member 2
Multidrug and toxin
extrusion protein 1
*Muscarinic acetylcholine
receptor M5
*Histamine H1 receptor
Muscarinic acetylcholine
receptor M1
Muscarinic acetylcholine
receptor M2
Muscarinic acetylcholine
receptor M3
Muscarinic acetylcholine
receptor M4
Potassium voltage-gated
channel subfamily H
member 2
Solute carrier family 22
member 1
Solute carrier family 22
member 2
Multidrug and toxin ex-
trusion protein 1
Muscarinic acetylcholine
receptor M4
*Muscarinic acetylcholine
receptor M5
*Histamine H1 receptor
Multidrug and toxin
extrusion protein 1
Muscarinic acetylcholine
receptor M1
Muscarinic acetylcholine
receptor M2
Muscarinic acetylcholine
receptor M3
Potassium voltage-gated
channel subfamily H
member 2
Solute carrier family 22
member 1
Solute carrier family 22
member 1
HIV-1 Reverse
Transcriptase
Dopamine
transporter
Serotonin
transporter
Norepinephrine
transporter
Serotonin
receptor 2A
Serotonin
receptor 2B
Serotonin
receptor 2C
Dopamine D5
receptor
*Muscarinic
acetylcholine
receptor M5
Dopamine D1
receptor
*Histamine H1
receptor
Adenylate
cyclase type V
Dopamine
transporter
Alpha-1a adren-
ergic receptor
Sigma opioid
receptor
Norepinephrine
transporter
Serotonin 2c
(5-HT2c)
receptor
See Table 4a for details.
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• The FMCT workflow may be used to generate reports of
possible side-effects of compound series being considered
for development into candidate drugs.
Further applications will become possible as additional
computational and analytic methods are encapsulated into
KNIME nodes. For example, at least two companies offer
KNIME nodes with ligand-protein docking functionalities
(www.schrodinger.com/knimeworkflows, http://www.
molsoft.com/gui/knime.html).
The workflows described here exemplify two modes of
accessing BindingDB data. In the first, KNIME nodes ac-
cess BindingDB’s web-services on-the-fly. This always uses
the most up-to-date results and does not require download-
ing and processing large files. In the second, the full
BindingDB dataset is processed into a KNIME table which
resides on the user’s computer. This avoids possible
network and server delays during use, is appropriate for
large-scale data access and allows the user to ensure repro-
ducibility of his or her query results. It also maximizes
privacy and allows for customized queries that go beyond
what is offered in the web-services. It is worth noting that
users wishing to adjust the criteria for winnowing
BindingDB’s large dataset into the local KNIME table can
do this by modifying the workflows used to build the
table, BDBBuilder, BDBBuilderFast or CondensedData.
Moreover, a full BindingDB data dump is available for
download, so users can set up their own local installations
of the entire database.
Predicting protein targets for compounds with
BindingDB data
The present study also illustrates the emergent value of a
large enough database of protein-ligand binding data, as a
tool to predict protein targets for compounds of interest.
Valuable data from a published application of the SEA
methodology (32) provided a platform to evaluate several
different FMCT implementations. Although the SEA and
FMCT studies are more anecdotal than statistical, they
nonetheless provide a useful initial picture of how the vari-
ous methods perform. Overall, the FMCT methods provide
excellent recovery of the target proteins correctly identified
by SEA. Although FMCT does miss several targets cor-
rectly identified by SEA, it also identifies valid or highly
plausible targets that do not appear to be highly ranked by
SEA. These differences between FMCT and SEA may result
from a combination of factors, including differences be-
tween the reference databases used, the application of a
10-mM affinity cutoff in the web-based SEA application,
and the different ways that chemical similarity is computed
and used to predict targets for query compounds. Thus, in
using the web-based SEA application we selected the
ChEMBL database; but ChEMBL does not include some
compound-protein affinity data present in BindingDB. It is
thus worth noting that the SEA web-page also allows one
to use alternative databases, including KEGG (72) and
WOMBAT (73). In addition, although SEA takes a holistic
statistical approach to associating compounds with poten-
tial targets, FMCT is based on simple pairwise compari-
sons of compounds, and the two approaches naturally
yield different, and seemingly complementary, target
predictions.
Of the similarity metrics tested here, the fast RDKit fin-
gerprint method performed as well as or better than the
more complex alternatives. However, the MCS similarity
metric occasionally provided interesting results distinct
from those provided by the fingerprint methods. Because
the MCS similarity metric is relatively slow to compute,
we tried using MCS to rerank a reduced set of targets al-
ready highly ranked by a fingerprint method, but, although
this saved computer time, it did not recover all the interest-
ing hits provided by the full MCS method. We also experi-
mented with accelerating FMCT by using a much smaller
reference dataset, which was constructed by clustering all
compounds in the full reference set according to chemical
similarity, and extracting a single representative compound
from each cluster. However, this approach led to substan-
tially reduced recovery of validated and plausible targets
for the query compounds examined here. The results might
be improved in future work by allowing a more generously
sized reference set in order to reduce the diversity of the
compounds in each cluster, and potentially by using a dif-
ferent clustering method.
For general users, it is worth pointing out that the core
fingerprint-based FMCT functionality is also freely access-
ible to users via interactive pages at the BindingDB website,
which does not require any familiarity with KNIME (www.
bindingdb.org/bind/chemsearch/marvin/FMCT.jsp). This
web implementation yields similar, but non-identical results,
as it employs a different set of chemical fingerprints, gener-
ated with JChem (74), to compute chemical similarity.
For users interested in KNIME, the present workflows
provide a starting point for development of novel imple-
mentations of FMCT, and for incorporation of this func-
tionality into more comprehensive workflows. For
example, one might employ other chemical similarity met-
rics, such as ones based on molecular shape (75–78) or
three-dimensional pharmacophore models based on avail-
able protein-ligand co-crystal structures. It is also interest-
ing to envision broader integrations, such as a merger of
FMCT predictions with natural language processing of the
scientific literature to automatically generate annotations
of genes and pathways with compound and targeting pre-
dictions; or the use of machine-learning techniques already
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available in KNIME nodes to craft more powerful chemin-
formatics analysis tools. Thus, the use of KNIME to ana-
lyze BindingDB data and to integrate it with additional
data types potentiates a range of useful biomedical and
translational applications.
Supplementary Data
Supplementary data are available at Database Online.
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